ReviewFrontiers in immunology2025

Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy.

Fan Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.